CATABASIS PHARMACEUTICALS IN's ticker is CATB and the CUSIP is 14875P107. A total of 1 filers reported holding CATABASIS PHARMACEUTICALS IN in Q4 2018. The put-call ratio across all filers is - and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2018 | $8,347,000 | -16.6% | 10,434,000 | 0.0% | 0.02% | -34.5% |
| Q2 2018 | $10,006,000 | +1631.1% | 10,434,000 | +6421.2% | 0.03% | +1350.0% |
| Q4 2016 | $578,000 | -14.9% | 160,000 | +45.1% | 0.00% | 0.0% |
| Q3 2016 | $679,000 | +52.9% | 110,250 | -8.1% | 0.00% | +100.0% |
| Q2 2016 | $444,000 | -26.6% | 120,000 | 0.0% | 0.00% | -50.0% |
| Q1 2016 | $605,000 | -4.6% | 120,000 | +50.0% | 0.00% | 0.0% |
| Q4 2015 | $634,000 | +56.5% | 80,000 | +60.0% | 0.00% | +100.0% |
| Q3 2015 | $405,000 | -33.7% | 50,000 | 0.0% | 0.00% | -50.0% |
| Q2 2015 | $611,000 | – | 50,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SV Health Investors, LLC | 2,857,667 | $23,118,000 | 12.93% |
| Clarus Ventures, LLC | 2,752,488 | $22,268,000 | 12.81% |
| Camber Capital Management LP | 1,000,000 | $8,090,000 | 0.69% |
| Rhenman & Partners Asset Management AB | 300,427 | $2,430,000 | 0.39% |
| SPHERA FUNDS MANAGEMENT LTD. | 327,476 | $2,595,000 | 0.33% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 628,482 | $5,084,000 | 0.20% |
| Spark Investment Management LLC | 32,500 | $263,000 | 0.03% |
| Tower Research Capital LLC (TRC) | 10,764 | $87,000 | 0.01% |
| VANGUARD GROUP INC | 4,732,472 | $168,937,000 | 0.01% |
| Alyeska Investment Group, L.P. | 40,220 | $325,000 | 0.00% |